SCHEDULE 13G/A: Major Shareholder Laurence Lytton Discloses 8.8% Stake in Cellectar Biosciences

Laurence W. Lytton has filed an amended Schedule 13G, disclosing an 8.8% beneficial ownership stake in Cellectar Biosciences, Inc., primarily through common stock and warrants.

Summary

• Laurence W. Lytton reported beneficial ownership of 3,955,470 shares of Cellectar Biosciences, Inc. Common Stock.
• This represents 8.8% of the company's outstanding Common Stock.
• The ownership consists of 503,296 shares of Common Stock and warrants to acquire an additional 3,452,174 shares.
• The warrants are subject to a 9.99% beneficial ownership limitation.
• The percentage is calculated based on 41,269,830 shares outstanding as of November 18, 2024, as reported in the Issuer's Form 10-Q for the quarter ended September 30, 2024.
• This filing is an Amendment No. 3 to a previous Schedule 13G.

Sentiment

Score: 5

Explanation: The document is a factual disclosure of beneficial ownership and does not contain qualitative statements that would indicate a positive or negative sentiment regarding company performance or outlook.

Positives

• A significant individual investor, Laurence W. Lytton, holds a substantial 8.8% stake, which may be interpreted as a sign of confidence in the company's future.

Future Outlook

NA

Industry Context

NA

Stakeholder Impact

• Shareholders: Provides transparency regarding a significant individual investor's stake, which may influence market perception and investor confidence.

Key Dates

Keywords

Cellectar Biosciences, Common Stock, Schedule 13G, Beneficial Ownership, Warrants, SEC Filing, Shareholder, Investment